Paul Biondi has hatched a new development deal at Flagship Pioneering, and this one comes wrapped with a $100 million cash bow arriving on the same day their discovery team is conducting an official ribbon-cutting ceremony for new office and lab space in Cambridge, MA. Pfizer and Flagship are each

Kristen Hege’s campaign to raise $500,000 to encourage the recruitment of women scientists into the Penn lab of Bruce Levine and Carl June is gaining some real momentum as the newly retired R&D executive makes her way along the Pacific Crest Trail. Bill Haney, the documentarian and biotech exec who

BridgeBio’s long wait for the final results of its Phase III trial of acoramidis is over. On Monday, the biotech said the 30-month readout of its drug in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) was a success, showing improvements in mortality, cardiovascular-related hospitalizations, a six-minute walk test and a biomarker

BridgeBio said it would share data on a critical Phase III trial on Monday morning, in what’s expected to be a make-or-break moment for the biotech. A few hours before the company announced the news, BridgeBio’s CEO Neil Kumar made a mysterious post on LinkedIn, sharing part of a translation

Five months ago, Rupert Vessey stepped out of his influential R&D post at Bristol Myers Squibb in a move clearly pointing to a new, though unannounced, chapter in biotech. And he unveiled his next career step today with the news that he’s joining a buzzy Flagship Pioneering as their chief